Cellectar Bio Stock Drops After ASCO Presentation on White Blood Cell Cancer Therapy

Cellectar Biosciences Inc CLRB announced updated data at the American Society of Clinical Oncology (ASCO) Annual Meeting from Phase 2 CLOVER-1 study of CLR 131 in relapsed/refractory B-cell hematologic cancers.
Data from 131 Waldenstrom’s macroglobulinemia (WM) patients showed a 100% (6/6) overall response rate, 83.3% major response rate, and a 16.7% complete response rate.
Median time to initial response was 22 days after the first infusion, while median time to major response, as defined as at least a 50% reduction in IgM, was 44 days after the first infusion.
Progression-free survival (PFS) for both MYD88 wild-type patients and the high-risk subgroup has not been reached after 18 months.
PFS for multidrug refractory patients was 11 months. The company also highlighted that Mean treatment-free remission is 1.1 years and remains ongoing.
See slide presentation here.
Price Action: CLRB shares are down 15.5% at $1.54 during the market session on the last check Friday.